RxDoctor Payments Data

Jessica Dean, DO

Family Medicine · Richardson, TXNPI 1518257294

Payments from drug & device makers

$13,632in general payments, 2019–2025

Across 730 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$948
  • Novo Nordisk$826
  • GSK$766
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$1,2009%
  • Travel & lodging$3042%
  • Food & beverage$12,11089%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,632 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,226
Medicare patients
154
Services billed
2,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$38,279
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$36,018
TrulicityDulaglutide17$33,172
FarxigaDapagliflozin Propanediol29$28,873
MounjaroTirzepatide18$24,711
JardianceEmpagliflozin11$14,650
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$5,441
Atorvastatin Calcium311$2,079
Levothyroxine Sodium182$1,845
PaxlovidNirmatrelvir/Ritonavir15$1,429
Losartan Potassium167$1,429
FenofibrateFenofibrate Nanocrystallized34$1,410
SynthroidLevothyroxine Sodium22$1,321
Rosuvastatin Calcium142$1,279
Olmesartan Medoxomil72$1,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$948$57,88335 claims
Novo NordiskOzempic$826$38,27937 claims
GSKTrelegy Ellipta$766$36,01831 claims
AstraZenecaFarxiga$1,312$28,87329 claims
Boehringer IngelheimJardiance$230$14,65011 claims
PfizerPaxlovid$502$1,42915 claims
AbbVieSynthroid$1,449$1,32122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →